- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04332042
TOFAcitinib in SARS-CoV2 Pneumonia
April 1, 2020 updated by: Armando Gabrielli, Università Politecnica delle Marche
TOFAcitinib in Patients With Early Onset SARS-CoV2 Interstitial Pneumonia
Immune-mediated lung injury plays a pivotal role in severe interstitial pnemumonia related to SARS-CoV2 infection.
Tofacitinib, a JAK1/3-Inhibitor, could mitigate alveolar inflammation by blocking IL-6 signal.
The aim of this prospective single cohort open study is to test the hypotesis that early administration of tofacitinib in patients with symptomatic pneumonia could reduce pulmonary flogosis, preventing function deterioration and the need of mechanical ventilation and/or admission in intensive care units.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Interstitial Pneumonia is the main complication of SARS-CoV2 infection.
Immune system hyperactivation, leading to alveolar inflammation, is the main mechanism in determining lung damage.
Evidence are accumulating about the pivotal role played by IL-6 in this disease.
Preliminary evidence, indeed, point out the efficacy of an IL-6 receptor inhibitor in improving clinical conditions in a proportion of rapidly deteriorating patients.
Our hypotesis is that a precocious inhibition of IL-6 signal, by the administration of tofacitinib (JAK 1/3 Inhibitor), could hinder the progression to more severe grades of lung inflammation leading to pulmonary function deterioration.
In a prospective single cohort open study, 50 patients admitted in Hospital due to SARS-CoV 2 symptomatic interstitial pneumonia, but not requiring mechanical ventilation, will be enrolled.
Tofacitinb will be administered every day for 14 days, starting within 24 h from the admission.
The primary outcome is to evaluate the effect of this drug on the rate of patients who will need mechanical ventilation.
Safety in this population will also be actively monitored.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Marche
-
Ancona, Marche, Italy, 60126
- Ospedali Riuniti di Ancona
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- SARS-CoV2 Infection diagnosed by rt-PCR
- Rx or CT-scan confirmed interstitial pneumonia
- Hospital admission from less than 24h
- Written Informed Consent
Exclusion Criteria:
- Age <18 ys or >65
- Patients in mechanical ventilation at time of admission
- Severe Hearth failure (NYHA 3 or 4)
- Severe History of Chronic Ischemic Hearth Disease, defined as history of Major Adverse Cardiovascular Event and/or recent (one year) revascularization.
- History of recurrent Deep Venous Thrombosis and Pulmonary Embolism
- Active Bacterial or Fungal Infection
- Hematological cancer
- Metastatic or intractable cancer
- Pre-existent neurodegenerative disease
- Severe Hepatic Impairment
- Severe Renal Failure (Creatinine Clearance <30ml/h)
- Active Herpes zoster infection
- Severe anemia (Hb<9g/dl)
- Lymphocyte count below 750/mcl
- Neutrophil count below 1000/mcl
- Platelet count below 50000/mcl
- Pregnancy or Lactation
- Inability to give informed consent (severe transitory or permanent mental impairment, incapacitation)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: tofacitinib
Tofacitinib cp 5mg: 2pills twice a day for 14 days
|
Tofacitinib 10mg twice a day will be administered within 24h from hospital admission for 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
need of mechanical ventilation
Time Frame: day 14
|
Rate of patients needing mechanical ventilation to maintain PaO2/FIO2>150 or, if PaO2 data not available, to maintain SO2>94% with FiO2 0,5.
|
day 14
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
need of admission in intensive care unit
Time Frame: day 14
|
Rate of patients needing admission to the intensive care unit for oro-tracheal intubation and/or evidence of Multiple Organ Disfunction
|
day 14
|
death
Time Frame: day 28
|
rate of patients dead
|
day 28
|
rate of adverse events
Time Frame: day 28
|
rate and type of adverse events
|
day 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Tian S, Hu W, Niu L, Liu H, Xu H, Xiao SY. Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer. J Thorac Oncol. 2020 May;15(5):700-704. doi: 10.1016/j.jtho.2020.02.010. Epub 2020 Feb 28.
- Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020 Feb 22;395(10224):e35-e36. doi: 10.1016/S0140-6736(20)30305-6. Epub 2020 Feb 5. No abstract available.
- Ashour HM, Elkhatib WF, Rahman MM, Elshabrawy HA. Insights into the Recent 2019 Novel Coronavirus (SARS-CoV-2) in Light of Past Human Coronavirus Outbreaks. Pathogens. 2020 Mar 4;9(3):186. doi: 10.3390/pathogens9030186.
- Rose-John S, Scheller J, Schaper F. "Family reunion"--A structured view on the composition of the receptor complexes of interleukin-6-type and interleukin-12-type cytokines. Cytokine Growth Factor Rev. 2015 Oct;26(5):471-4. doi: 10.1016/j.cytogfr.2015.07.011. Epub 2015 Jul 6. No abstract available.
- McInnes IB, Byers NL, Higgs RE, Lee J, Macias WL, Na S, Ortmann RA, Rocha G, Rooney TP, Wehrman T, Zhang X, Zuckerman SH, Taylor PC. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019 Aug 2;21(1):183. doi: 10.1186/s13075-019-1964-1.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
April 10, 2020
Primary Completion (Anticipated)
June 20, 2020
Study Completion (Anticipated)
July 10, 2020
Study Registration Dates
First Submitted
March 28, 2020
First Submitted That Met QC Criteria
April 1, 2020
First Posted (Actual)
April 2, 2020
Study Record Updates
Last Update Posted (Actual)
April 2, 2020
Last Update Submitted That Met QC Criteria
April 1, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TOFACoV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-COv2 Related Interstitial Pneumonia
-
Institute of Biophysics and Cell Engineering of...Belarusian State Medical UniversityCompletedPneumonia, Viral | Pneumonia | Covid-19 | COVID | Coronavirus | Sars-CoV2 | Pneumonia, InterstitialBelarus
-
Collegium Medicum w BydgoszczyRecruitingSARS-CoV2 Infection | SARS-CoV2 AntibodiesPoland
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Meshalkin Research Institute of Pathology of CirculationUnknown
-
Collegium Medicum w BydgoszczyActive, not recruitingSARS-CoV2 Infection | SARS-CoV2 AntibodiesPoland
-
University Hospital, LilleCompleted
-
CHU de ReimsUnknownSevere SARS-CoV2 PneumoniaFrance
-
BioNTech SECompletedCOVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)United States, Germany, Turkey, South Africa
-
Hospital Ambroise Paré ParisEnrolling by invitationCOVID | Sars-CoV2France
-
Andalusian Network for Design and Translation of...Completed
Clinical Trials on Tofacitinib
-
PfizerCompletedAnkylosing SpondylitisKorea, Republic of, United States, Spain, Taiwan, Canada, Czech Republic, Poland, Hungary, Germany, Russian Federation
-
PfizerCompleted
-
PfizerCompletedPlaque PsoriasisUnited States
-
PfizerCompleted
-
Nanfang Hospital of Southern Medical UniversityJiangsu Simcere Pharmaceutical Co., Ltd.Not yet recruitingRheumatoid Arthritis
-
PfizerCompleted
-
PfizerCompletedJuvenile Idiopathic ArthritisUnited States, Spain, Turkey, Canada, Australia, Israel, United Kingdom, Argentina, Brazil, Poland, Mexico, Belgium, Russian Federation, Ukraine
-
Stanford UniversityNational Institutes of Health (NIH)RecruitingDiaphragm InjuryUnited States